Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713321 · ClinicalTrials.gov registry record
Impact of Medicaid Health Home on Patients With Diabetes in New York City
A clinical trial of Type 2 Diabetes Mellitus, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 96,759
- Enrollment target
- 1
- Study location
NCT02713321: Completed study of Type 2 Diabetes Mellitus, sponsored by Icahn School of Medicine at Mount Sinai.
NCT02713321 is a study of Type 2 Diabetes Mellitus that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 96,759 participants, above the 2,216-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (4266% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02713321, a study of Type 2 Diabetes Mellitus, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 96,759 participants
- Enrollment target
- 1
- Study location
Study Summary
Type 2 diabetes is common in the United States; about 1 in 10 people have the disease. Diabetes can cause devastating health events, such as hospitalizations, kidney failure, blindness, amputation, heart attack, stroke, painful nerve damage (neuropathy), and death. There are many barriers for patients with diabetes that get in the way of controlling risk factors, following recommendations, and getting the care they need from the health system to help prevent these complications; this is especially true for those with other health problems too. Those living in poverty and racial/ethnic minorities are more likely to have complications from diabetes, and less likely to get recommended care from health systems. In order to improve care and outcomes for people with complex medical problems, several states have started the Medicaid Health Home (HH) program, including New York State (NYS) in 2012. This program is for people with two or more chronic health conditions, such as diabetes and heart disease, people with HIV, and people with a serious mental health condition. HHs are meant to manage and coordinate care, by helping health care providers, social service agencies, community-based organizations, and health insurance plans work together. Similar programs have been shown, on a smaller scale, to improve some results for patients with diabetes, such as lab tests indicating level of diabetes control. Studies have not yet looked at how a large program like HHs impacts the way healthcare is delivered and impacts the health events that matter most to patients with diabetes. Also, few studies include stakeholders on the research team, even though they stand to benefit the most from such programs, and have the experience needed as patients, clinicians, advocates, and administrators to guide efforts. The investigators have gathered a research team that includes scientific investigators along with a diverse group of partners, including patients, clinicians, and program administr
Primary Outcome
Proportion of hospitalizations related to diabetes that could have been prevented. Diabetes-related potentially preventable hospitalizations are admissions to a hospital for certain acute illnesses or worsening chronic conditions that might not have required hospitalization had these conditions been managed successfully by primary care providers in outpatient settings.
Conditions Studied
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96,759 participants |
| Start Date | 2017-01-24 |
| Est. Completion | 2021-08-31 |
What the finished NCT02713321 record still lists
NCT02713321 is an observational study that tracks outcomes without assigning an intervention. Its 96,759 participants enrollment target places it among the larger protocols in the corpus, above the 2,216-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (4266% higher).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.
NCT02713321 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02713321 about?
NCT02713321 is a clinical study titled "Impact of Medicaid Health Home on Patients With Diabetes in New York City". Type 2 diabetes is common in the United States; about 1 in 10 people have the disease. Diabetes can cause devastating health events, such as hospitalizations, kidney failure, blindness, amputation, heart attack, stroke, painful nerve damage (neuropathy), and death. There are many barriers for patien...
What is the current status of trial NCT02713321?
This trial is currently completed. The enrollment target is 96,759 participants. The study started on 2017-01-24. Estimated completion is 2021-08-31.
What conditions does trial NCT02713321 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
Who is sponsoring clinical trial NCT02713321?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02713321 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02713321's enrollment target sits among peer trials
96,759 2nd of 130 the highest of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System
RECRUITING
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
RECRUITING
-
Preventing Type 2 Diabetes in Black Emergent Adult
RECRUITING · NA
-
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
RECRUITING
-
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01351545 · 99,999 participants
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI